What's in Epicentre's pipeline?

Epicentre has 11 drugs in our index: 7 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Epicentre's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, University of Oxford, Centers for Disease Control and Prevention, Sanofi Pasteur, a Sanofi Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/epicentre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Epicentre — Portfolio Competitive Intelligence Brief

Epicentre pipeline: 7 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Artesunate-amodiaquine fixed-dose combination	Artesunate-amodiaquine fixed-dose combination	marketed	Antimalarial combination	Plasmodium falciparum (multiple parasite targets)	Infectious Disease
Yellow fever vaccine, Bio-Manguinhos	Yellow fever vaccine, Bio-Manguinhos	marketed
Yellow fever vaccine, Chumakov Institute	Yellow fever vaccine, Chumakov Institute	marketed
Delayed second dose of oral cholera vaccine, Euvichol-Plus	Delayed second dose of oral cholera vaccine, Euvichol-Plus	marketed
Stamaril, Sanofi Pasteur	Stamaril, Sanofi Pasteur	marketed	Live attenuated vaccine	Yellow fever virus (17D strain)	Immunology / Infectious Disease
PCV10 full dose	PCV10 full dose	marketed	Pneumococcal conjugate vaccine		Immunology
PCV10 fractional dose	PCV10 fractional dose	marketed
Rotavirus vaccine (BRV-PV)	Rotavirus vaccine (BRV-PV)	phase 3	Live attenuated vaccine		Immunology / Infectious Disease

Therapeutic area mix

Infectious Disease · 3
Immunology / Infectious Disease · 2
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Sanofi · 4 shared drug classes
University of Oxford · 4 shared drug classes
Centers for Disease Control and Prevention · 3 shared drug classes
Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
London School of Hygiene and Tropical Medicine · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Bandim Health Project · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Epicentre:

Cite this brief

Drug Landscape (2026). Epicentre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/epicentre. Accessed 2026-05-14.